更新于：2024-11-01

CD-30 positive pleomorphic large T-cell cutaneous lymphoma

CD30阳性多形大T细胞皮肤淋巴瘤

更新于：2024-11-01

基本信息

别名

CD-30 positive pleomorphic large T-cell cutaneous lymphoma、CD-30 positive pleomorphic large T-cell cutaneous lymphoma (disorder)、CD30+ pleomorphic large T-cell cutaneous lymphoma

+ [1]

简介-

关联

项与 CD30阳性多形大T细胞皮肤淋巴瘤相关的药物

Brentuximab Vedotin

维布妥昔单抗

靶点

CD30 x Tubulin

作用机制

CD30抑制剂 [+1]

在研机构

Seagen Inc. [+9]

原研机构

Seagen Inc.

在研适应症

CD30-Positive recurrent or refractory Cutaneous T-Cell Lymphoma [+32]

非在研适应症

急性淋巴细胞白血病 [+42]

最高研发阶段批准上市

首次获批国家/地区

美国

首次获批日期2011-08-19

anti-CD30 Bispecific Antibody-armed anti-CD3-Activated Autologous T-cells(Medical College of Wisconsin)

靶点

CD3 x CD30

作用机制

CD3刺激剂 [+1]

在研机构

Medical College of Wisconsin

原研机构

Medical College of Wisconsin

在研适应症

间变性大细胞淋巴瘤 [+4]

非在研适应症-

最高研发阶段临床1/2期

首次获批国家/地区-

首次获批日期1800-01-20

项与 CD30阳性多形大T细胞皮肤淋巴瘤相关的临床试验

NCT05544968 / Not yet recruiting临床1/2期IIT

Phase I Dose Escalation and Expansion Study to Investigate the Safety, Tolerability, and Preliminary Efficacy of Anti-CD30 Bispecific Antibody-armed Anti-CD3-Activated Autologous T-cells (CD30 biAb-AATC) in Patients With Relapsed/Refractory CD30 Positive Hematopoietic Malignancies

This first-in-human trial will assess the safety, feasibility, and efficacy of an immunotherapy with a novel CD30 antibody conjugated to a CD3 antibody that is preloaded onto a patient's own T-cells, generating a CD30 bispecific antibody-armed, anti-CD3-activated, autologous T-cells (CD30 biAb-AATC).

开始日期2024-12-01

申办/合作机构

Medical College of Wisconsin

NCT01352520 / Active, not recruiting临床2期IIT

Phase II Trial of Brentuximab Vedotin (SGN-35) at Dose of 1.8 mg/kg IV Every 3 Weeks in Patients With CD30-positive Lymphoproliferative Disorders (Cutaneous Anaplastic Large T-cell Lymphoma (ALCL), Mycosis Fungoides, and Extensive Lymphomatoid Papulosis (LyP)

The goal of this clinical research study is to learn if SGN-35 (brentuximab vedotin) can help to control ALCL, LyP or MF in patients with at least 1 of the 3 skin lymphomas. The safety of the study drug will also be studied.

开始日期2011-06-01

申办/合作机构

The University of Texas MD Anderson Cancer Center

[+1]

100 项与 CD30阳性多形大T细胞皮肤淋巴瘤相关的临床结果

登录后查看更多信息

100 项与 CD30阳性多形大T细胞皮肤淋巴瘤相关的转化医学

登录后查看更多信息

0 项与 CD30阳性多形大T细胞皮肤淋巴瘤相关的专利（医药）

登录后查看更多信息

项与 CD30阳性多形大T细胞皮肤淋巴瘤相关的文献（医药）

2021-08-01·Virchows Archiv3区 · 医学

Is immunohistochemical expression of GATA3 helpful in the differential diagnosis of transformed mycosis fungoides and primary cutaneous CD30-positive T cell lymphoproliferative disorders?

3区 · 医学

Article

作者: Nagarajan, Priyadharsini ; Tetzlaff, Michael T ; Aung, Phyu P ; Miranda, Roberto N ; Huen, Auris ; Gu, Jun ; Prieto, Victor G ; Vega, Francisco ; Collins, Katrina ; Torres-Cabala, Carlos A ; Curry, Jonathan L ; Ivan, Doina ; Duvic, Madeleine

Mycosis fungoides with large cell transformation (MFLCT) can be difficult to distinguish from primary cutaneous CD30+ T cell lymphoproliferative disorders (PC CD30+ LPD), especially primary cutaneous anaplastic large cell lymphoma (PC-ALCL). This diagnostic distinction is critical for appropriate patient management. GATA3 has been proposed to be useful in the discrimination between these two entities. We identified 25 cases of MFLCT and 24 cases of PC CD30+ LPDs (including lymphomatoid papulosis (n=14), PC-ALCL (n=6), and CD30+ LPD, not otherwise specified (n=4)) diagnosed at our institution from 2002 to 2019. Sections from archived specimens were stained to evaluate for GATA3 expression by immunohistochemistry and compared among cutaneous CD30+ T cell LPDs. The majority of the MFLCT cohort had strong, diffuse expression of GATA3 ranging from 0 to 100% of dermal T cells (mean 53.20%) with 15/25 cases (60%) showing GATA3 expression greater than 50%, while the PC CD30+ LPD group showed variable, moderate GATA3 labeling ranging from 0 to 60% of dermal T cells (mean 23.26%), with 5/6 cases (83%) showing GATA3 expression less than 40% (p =0.003). The calculated sensitivity and specificity were 56% and 74%, while positive and negative predictive values were 70% and 61%, respectively. Based on the percent staining of positive cells, using 50% as a cutoff value for expression, GATA3 might be a useful immunohistochemical marker to discriminate MFLCT from PC CD30+ LPDs, including PC-ALCL.

2018-06-01·Annales de Dermatologie et de Vénéréologie4区 · 医学

Lymphoprolifération cutanée primitive CD30+ sous fingolimod : un cas et revue systématique de la littérature

4区 · 医学

Review

作者: Francès, C ; Senet, P ; Moguelet, P ; Duriez, P ; Chasset, F ; Cesbron, E ; Barbaud, A ; Monfort, J-B ; Giannesini, C

BACKGROUNDFingolimod is an oral immunomodulator approved for relapsing-remitting multiple sclerosis. We report a case of a primary cutaneous CD30+ T-cell lymphoproliferation occurring 6 months after initiation of fingolimod. Based on a systematic literature review, the characteristics of these fingolimod-induced lymphoproliferative disorders are described.PATIENTS AND METHODSA 56-year-old woman developed cutaneous indurated and ulcerated nodular lesions 6 months after starting fingolimod for active relapsing-remitting multiple sclerosis. Histological examination of a punch biopsy sample demonstrated a polymorphous dermal infiltrate containing large atypical CD30+ cells, leading to diagnosis of primary cutaneous CD30+ anaplastic large-cell lymphoma. Chest-abdomen-pelvis CT scans were performed to rule out secondary cutaneous anaplastic large-cell lymphoma. Spontaneous clinical regression was observed and after assessing the benefit/risk ratio, it was decided to continue fingolimod under strict surveillance, with no relapse occurring by month 18.DISCUSSIONA systematic review of PUBMED/Medline and Embase identified seven other cases of lymphoproliferative disorders occurring during fingolimod treatment, including two other cases of primitive cutaneous CD30+ lymphoproliferative disorders.CONCLUSIONEven if cutaneous CD30+ lymphoproliferative disorders occur only rarely during fingolimod treatment, dermatologists should nevertheless be aware of this association for which strict dermatological surveillance is required. We would also stress that these CD30+ lymphoproliferative disorders can disappear spontaneously, as in our case, even if treatment by fingolimod is continued.

2016-07-01·Aesthetic Surgery Journal2区 · 医学

Biomarkers Provide Clues to Early Events in the Pathogenesis of Breast Implant-Associated Anaplastic Large Cell Lymphoma

2区 · 医学

Article

作者: Epstein, Alan L ; Brody, Garry S ; MacLeod, Roderick A F ; Adams, William P ; Morgan, John ; Khare, Pranay ; Xu, Haiying ; Deva, Anand ; Van Natta, Bruce W ; Kadin, Marshall E

Almost 200 women worldwide have been diagnosed with breast implant-associated anaplastic large cell lymphoma (BIA-ALCL). The unique location and specific lymphoma type strongly suggest an etio-pathologic link between breast implants and BIA-ALCL. It is postulated that chronic inflammation via bacterial infection may be an etiological factor. BIA-ALCL resembles primary cutaneous ALCL (pcALCL) in morphology, activated T-cell phenotype, and indolent clinical course. Gene expression array analysis, flow cytometry, and immunohistochemistry were used to study pcALCL and BIA-ALCL cell lines. Clinical samples were also studied to characterize transcription factor and cytokine profiles of tumor cells and surrounding lymphocytes. BIA-ALCL and pcALCL were found to have common expression of transcription factors SOCS3, JunB, SATB1, and a cytokine profile suggestive of a Th1 phenotype. Similar patterns were observed in a CD30+ cutaneous lymphoproliferative disorder (LPD). The patterns of cytokine and transcription factor expression suggest that BIA-ALCL is likely to arise from chronic bacterial antigen stimulation of T-cells. Further analysis of cytokine and transcription factor profiles may allow early detection and treatment of BIA-ALCL leading to better prognosis and survival. LEVEL OF EVIDENCE 5: Risk.